Spyre Therapeutics Stock Performance
| SYRE Stock | 27.65 0.78 2.74% |
The entity has a beta of 2.38, which indicates a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Spyre Therapeutics will likely underperform. Spyre Therapeutics right now has a risk of 3.51%. Please validate Spyre Therapeutics expected short fall, as well as the relationship between the rate of daily change and period momentum indicator , to decide if Spyre Therapeutics will be following its existing price patterns.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Spyre Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of rather sound basic indicators, Spyre Therapeutics is not utilizing all of its potentials. The latest stock price tumult, may contribute to shorter-term losses for the shareholders. ...more
Actual Historical Performance (%)
One Day Return (2.74) | Five Day Return (0.47) | Year To Date Return 29.21 | Ten Year Return (88.68) | All Time Return (88.68) |
Last Split Factor 1:25 | Last Split Date 2023-09-08 |
1 | Insider Trading | 10/01/2024 |
2 | Spyre Therapeutics Announces Expected Acceleration of SPY003 Clinical Timelines and Presentations at UEGW supporting Spyres Portfolio of Potentially Best-in-Cla... | 10/14/2024 |
3 | Acquisition by Sloan Sheldon of 400000 shares of Spyre Therapeutics at 27.46 subject to Rule 16b-3 | 10/16/2024 |
4 | Disposition of 300 shares by Albers Jeffrey W. of Spyre Therapeutics at 36.43 subject to Rule 16b-3 | 10/25/2024 |
5 | Disposition of 6700 shares by Albers Jeffrey W. of Spyre Therapeutics at 36.7631 subject to Rule 16b-3 | 11/06/2024 |
6 | Spyre Therapeutics director Jeffrey Albers sells 246,312 in stock | 11/08/2024 |
7 | Deep Track Capital, LP Adjusts Stake in Spyre Therapeutics Inc | 11/14/2024 |
8 | Spyre Therapeutics Announces Proposed Public Offering of its Common Stock and Pre-Funded Warrants | 11/18/2024 |
9 | Spyre Therapeutics Shares Gap Down Time to Sell | 11/21/2024 |
10 | Spyre Therapeutics Announces First Participants Dosed in Phase 1 Trials of Novel Half-life Extended Anti-TL1A Antibodies | 12/02/2024 |
| Begin Period Cash Flow | 36.4 M |
Spyre |
Spyre Therapeutics Relative Risk vs. Return Landscape
If you would invest 2,800 in Spyre Therapeutics on September 4, 2024 and sell it today you would lose (35.00) from holding Spyre Therapeutics or give up 1.25% of portfolio value over 90 days. Spyre Therapeutics is currently generating 0.0419% in daily expected returns and assumes 3.5144% risk (volatility on return distribution) over the 90 days horizon. In different words, 31% of stocks are less volatile than Spyre, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Spyre Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Spyre Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Spyre Therapeutics, and traders can use it to determine the average amount a Spyre Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0119
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | SYRE |
Estimated Market Risk
| 3.51 actual daily | 31 69% of assets are more volatile |
Expected Return
| 0.04 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| 0.01 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Spyre Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Spyre Therapeutics by adding Spyre Therapeutics to a well-diversified portfolio.
Spyre Therapeutics Fundamentals Growth
Spyre Stock prices reflect investors' perceptions of the future prospects and financial health of Spyre Therapeutics, and Spyre Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Spyre Stock performance.
| Return On Equity | -0.92 | ||||
| Return On Asset | -0.39 | ||||
| Current Valuation | 1.51 B | ||||
| Shares Outstanding | 58.71 M | ||||
| Price To Book | 9.73 X | ||||
| Price To Sales | 2,210 X | ||||
| Revenue | 886 K | ||||
| EBITDA | (242.3 M) | ||||
| Net Income | (338.79 M) | ||||
| Total Debt | 84.56 M | ||||
| Book Value Per Share | 3.34 X | ||||
| Cash Flow From Operations | (99.91 M) | ||||
| Earnings Per Share | (37.90) X | ||||
| Market Capitalization | 1.67 B | ||||
| Total Asset | 341.86 M | ||||
| Retained Earnings | (764.41 M) | ||||
| Working Capital | 309.55 M | ||||
About Spyre Therapeutics Performance
By analyzing Spyre Therapeutics' fundamental ratios, stakeholders can gain valuable insights into Spyre Therapeutics' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Spyre Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Spyre Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.99) | (1.04) | |
| Return On Capital Employed | (0.78) | (0.82) | |
| Return On Assets | (0.99) | (1.04) | |
| Return On Equity | (1.84) | (1.93) |
Things to note about Spyre Therapeutics performance evaluation
Checking the ongoing alerts about Spyre Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Spyre Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Spyre Therapeutics had very high historical volatility over the last 90 days | |
| The company reported the previous year's revenue of 886 K. Net Loss for the year was (338.79 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Spyre Therapeutics generates negative cash flow from operations | |
| Spyre Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Over 88.0% of the company shares are owned by institutional investors | |
| Latest headline from finance.yahoo.com: Spyre Therapeutics Announces First Participants Dosed in Phase 1 Trials of Novel Half-life Extended Anti-TL1A Antibodies |
- Analyzing Spyre Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Spyre Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Spyre Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Spyre Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Spyre Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Spyre Therapeutics' stock. These opinions can provide insight into Spyre Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Spyre Stock analysis
When running Spyre Therapeutics' price analysis, check to measure Spyre Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Spyre Therapeutics is operating at the current time. Most of Spyre Therapeutics' value examination focuses on studying past and present price action to predict the probability of Spyre Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Spyre Therapeutics' price. Additionally, you may evaluate how the addition of Spyre Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Commodity Directory Find actively traded commodities issued by global exchanges |